Influence of melatonin on the proliferative and apoptotic responses of the prostate under normal and hyperglycemic conditions

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Gobbo, Marina G ^a   Dizeyi, Nishtman ^b   Abrahamsson, Per Anders ^b   Bertilsson, Per Anders ^b   Masitéli, Viviane Sanches ^c   Pytlowanciv, Eloisa Zanin ^a   Taboga, Sebastião R ^c   Góes, Rejane M ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DRINKING WATER; GLUCOSE; MELATONIN; MELATONIN RECEPTOR; STREPTOZOCIN; TESTOSTERONE; CULTURE MEDIUM; CYCLINE; GLUCOSE BLOOD LEVEL; HORMONE; MELATONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERGLYCEMIA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WISTAR RAT; ANIMAL; BLOOD; BODY WEIGHT; CELL LINE; CELL SURVIVAL; CHEMISTRY; CULTURE MEDIUM; EPITHELIUM CELL; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA; EPITHELIAL CELLS; FLOW CYTOMETRY; HORMONES; HUMANS; HYPERGLYCEMIA; MALE; MELATONIN; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE; RATS; RATS, WISTAR; RECEPTOR, MELATONIN, MT2;

EID: 84939181963     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/538529     Document Type: Article

References (75)

1. R. J. Reiter and D.-X. Tan, "Melatonin: amultitaskingmolecule," Progress in Brain Research, vol. 181, pp. 127-151, 2010.
2. R. J. Reiter, D.-X. Tan, L. C. Manchester, S. D. Paredes, J. C. Mayo, and R. M. Sainz, "Melatonin and reproduction revisited," Biology of Reproduction, vol. 81, no. 3, pp. 445-456, 2009.
3. P. L. Montilla, J. F. Vargas, I. F. Túnez, M. C. Muñoz, M. E. D. Valdelvira, and E. S. Cabrera, "Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin," Journal of Pineal Research, vol. 25, no. 2, pp. 94-100, 1998.
4. S. R. Pandi-Perumal, V. Srinivasan, G. J. M. Maestroni, D. P. Cardinali, B. Poeggeler, and R. Hardeland, "Melatonin: natures most versatile biological signal?" FEBS Journal, vol. 273, no. 13, pp. 2813-2838, 2006.
5. R. J. Reiter, "Melatonin: lowering the high price of free radicals," News in Physiological Sciences, vol. 15, no. 5, pp. 246-250, 2000.
6. H. Vural, T. Sabuncu, S. O. Arslan, and N. Aksoy, "Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats," Journal of Pineal Research, vol. 31, no. 3, pp. 193-198, 2001.
7. N. Mohan, K. Sadeghi, R. J. Reiter, and M. L. Meltz, "The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappaB," Biochemistry and Molecular Biology International, vol. 37, no. 6, pp. 1063-1070, 1995.
8. F. Radogna, M. Diederich, and L. Ghibelli, "Melatonin: a pleiotropic molecule regulating inflammation," Biochemical Pharmacology, vol. 80, no. 12, pp. 1844-1852, 2010.
9. M. Becker-André, I. Wiesenberg, N. Schaeren-Wiemers et al., "Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily," The Journal of Biological Chemistry, vol. 269, no. 46, pp. 28531-28534, 1994.
10. I. Wiesenberg, M. Missbach, J.-P. Kahlen, M. Schrader, and C. Carlberg, "Transcriptional activation of the nuclear receptor RZRβ by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand ," Nucleic Acids Research, vol. 23, no. 3, pp. 327-333, 1995.
11. D. Acuna-Castroviejo, G. Escames, M. I. Rodriguez, and L. C. Lopez, "Melatonin role in themitochondrial function," Frontiers in Bioscience, vol. 12, no. 3, pp. 947-963, 2007.
12. G. Benítez-King, L. Huerto-Delgadillo, and F. Antón-Tay, "Melatonin effects on the cytoskeletal organization of MDCK and neuroblastoma N1E-115 cells," Journal of Pineal Research, vol. 9, no. 3, pp. 209-220, 1990.
13. O. Nosjean, M. Ferro, F. Cogé, et al., "Identification of the melatonin-binding site 3 as the quinone reductase 2," The Journal of Biological Chemistry, vol. 275, no. 40, pp. 31311-31317, 2000.
14. E. Gilad, M. Laudon, H. Matzkin, and N. Zisapel, "Evidence for a local action of melatonin on the rat prostate," Journal of Urology, vol. 159, no. 3, pp. 1069-1073, 1998.
15. R. Paroni, L. Terraneo, F. Bonomini, et al., "Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling," Journal of Pineal Research, vol. 57, no. 1, pp. 43-52, 2014.
16. S. W. F. Siu, K. W. Lau, P. C. Tam, and S. Y. W. Shiu, "Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and and rogen sensitivity," Prostate, vol. 52, no. 2, pp. 106-122, 2002.
17. S. C. Xi, S. W. F. Siu, S. W. Fong, and S. Y. W. Shiu, "Inhibition of and rogen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression," Prostate, vol. 46, no. 1, pp. 52-61, 2001.
18. M. M. Marelli, P. Limonta, R. Maggi, M. Motta, and R. M. Moretti, "Growth-inhibitory activity of melatonin on human and rogen-independent DU 145 prostate cancer cells," Prostate, vol. 45, no. 3, pp. 238-244, 2000.
19. R. M. Moretti, M. M. Marelli, R. Maggi, D. Dondi, M. Motta, and P. Limonta, "Antiproliferative action of melatonin on human prostate cancer LNCaP cells," Oncology Reports, vol. 7, no. 2, pp. 347-351, 2000.
20. J.-W. Park, M.-S. Hwang, S.-I. Suh, and W.-K. Baek, "Melatonin down-regulates HIF-1α expression through inhibition of protein translation in prostate cancer cells," Journal of Pineal Research, vol. 46, no. 4, pp. 415-421, 2009.
21. A. Rimler, Z. Culig, G. Levy-Rimler, et al., "Melatonin elicits nuclear exclusion of the human and rogen receptor and attenuates its activity," Prostate, vol. 49, no. 2, pp. 145-154, 2001.
22. A. Rimler, Z. Culig, Z. Lupowitz, and N. Zisapel, "Nuclear exclusion of the and rogen receptor by melatonin," Journal of Steroid Biochemistry and Molecular Biology, vol. 81, no. 1, pp. 77-84, 2002.
23. E. J. Sohn, G. Won, J. Lee, S. Lee, and S.-H. Kim, "Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells," Journal of Cancer, vol. 6, no. 1, pp. 19-28, 2015.
24. C. W. Tam, K. W. Chan, V. W. S. Liu, B. Pang, K.-M. Yao, and S. Y. W. Shiu, "Melatonin as a negativemitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance," Journal of Pineal Research, vol. 45, no. 4, pp. 403-412, 2008.
25. C. W. Tam and S. Y. W. Shiu, "Functional interplay between melatonin receptor-mediated antiproliferative signaling and and rogen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer," Journal of Pineal Research, vol. 51, no. 3, pp. 297-312, 2011.
26. S. S. Joo and Y.-M. Yoo, "Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer," Journal of Pineal Research, vol. 47, no. 1, pp. 8-14, 2009.
27. A. Rodriguez-Garcia, J. C. Mayo, D. Hevia, I. Quiros-Gonzalez, M. Navarro, and R. M. Sainz, "Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis," Journal of Pineal Research, vol. 54, no. 1, pp. 33-45, 2013.
28. Z. Culig, J. Stober, A. Gast, et al., "Activation of two mutant and rogen receptors fromhuman prostatic carcinoma by adrenal and rogens and metabolic derivatives of testosterone," Cancer Detection and Prevention, vol. 20, no. 1, pp. 68-75, 1996.
29. D. Hevia, R. M. Sainz, D. Blanco, et al., "Melatonin uptake in prostate cancer cells: intracellular transport versus simple passive diffusion," Journal of Pineal Research, vol. 45, no. 3, pp. 247-257, 2008.
30. W. D. Tilley, J. M. Bentel, J. O. Aspinall, R. E. Hall, and D. J. Horsfall, "Evidence for a novel mechanism of and rogen resistance in the human prostate cancer cell line, PC-3," Steroids, vol. 60, no. 1, pp. 180-186, 1995.
31. M. B. Frungieri, A. Mayerhofer, K. Zitta, O. P. Pignataro, R. S. Calandra, and S. I. Gonzalez-Calvar, "Direct effect of melatonin on Syrian hamster testes: melatonin subtype 1a receptors, inhibition of and rogen production, and interaction with the local corticotropin-releasing hormone system," Endocrinology, vol. 146, no. 3, pp. 1541-1552, 2005.
32. B. Yilmaz, S. Kutlu, R. Mogulkoc, et al., "Melatonin inhibits testosterone secretion by acting at hypothalamo-pituitarygonadal axis in the rat," Neuroendocrinology Letters, vol. 21, no. 4, pp. 301-306, 2000.
33. A. Barbosa-Desongles, C. Hernández, I. De Torres, et al., "Diabetes protects from prostate cancer by downregulating and rogen receptor: new insights fromLNCaP cells and PAC120 mouse model," PLoS ONE, vol. 8, no. 9, Article ID e74179, 2013.
34. V. H. A. Cagnon, A. M. Camargo, R. M. Rosa, R. Fabiani, C. R. Padovani, and F. E. Martinez, "Ultrastructural study of the ventral lobe of the prostate ofmice with streptozotocin induced diabetes (C57BL/6J)," Tissue and Cell, vol. 32, no. 4, pp. 275-283, 2000.
35. V. H. Cagnon and W. J. Fávaro, "Dystroglycan patterns on the prostate of non-obese diabetic mice submitted to glycaemic control," International Journal of Experimental Pathology, vol. 90, no. 2, pp. 156-165, 2009.
36. C. F. Carvalho, M. Camargo, V. H. Cagnon, and C. R. Padovani, "Effects of experimental diabetes on the structure and ultrastructure of the coagulating gland of C57BL/6J and NOD mice," The Anatomical Record, vol. 270, no. 2, pp. 129-136, 2003.
37. W. J. Fávaro, C. R. Padovani, and V. H. A. Cagnon, "Ultrastructural and proliferative features of the ventral lobe of the prostate in non-obese diabetic mice (NOD) following and rogen and estrogen replacement associated to insulin therapy," Tissue and Cell, vol. 41, no. 2, pp. 119-132, 2009.
38. W. J. Fávaro and V. H. A. Cagnon, "Effect of combined hormonal and insulin therapy on the steroid hormone receptors and growth factors signalling in diabetic mice prostate," International Journal of Experimental Pathology, vol. 91, no. 6, pp. 537-545, 2010.
39. E. M. Porto, S. A. D. A. D. Santos, L. M. Ribeiro, et al., "Lobe variation effects of experimental diabetes and insulin replacement on rat prostate," Microscopy Research and Technique, vol. 74, no. 11, pp. 1040-1048, 2011.
40. D. L. Ribeiro, E. J. Caldeira, E. M. Cândido, A. J. Manzato, S. R. Taboga, and V. H. Cagnon, "Prostatic stromal microenvironment and experimental diabetes," European Journal of Histochemistry, vol. 50, no. 1, pp. 51-60, 2006.
41. C. Ye, X. Li, Y. Wang, et al., "Diabetes causes multiple genetic alterations and downregulates expression of DNA repair genes in the prostate," Laboratory Investigation, vol. 91, no. 9, pp. 1363-1374, 2011.
42. M. Yono, S. M. Mane, A. Lin, R. M. Weiss, and J. Latifpour, "Differential effects of diabetes induced by streptozotocin and that develops spontaneously on prostate growth in Bio Breeding (BB) rats," Life Sciences, vol. 83, no. 5-6, pp. 192-197, 2008.
43. F. O. Arcolino, D. L. Ribeiro, M. G. Gobbo, S. R. Taboga, and R. M. Goes, "Proliferation and apoptotic rates and increased frequency of p63-positive cells in the prostate acinar epithelium of alloxan-induced diabetic rats," International Journal of Experimental Pathology, vol. 91, no. 2, pp. 144-154, 2010.
44. J. P. Burke, D. J. Jacobson, M. E. McGree, et al., "Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota," Urology, vol. 67, no. 1, pp. 22-25, 2006.
45. M. G. Gobbo, S. R. Taboga, D. L. Ribeiro, and R. M. Góes, "Short-term stromal alterations in the rat ventral prostate following alloxan-induced diabetes and the influence of insulin replacement," Micron, vol. 43, no. 2-3, pp. 326-333, 2012.
46. D. L. Ribeiro, S. F. G. Marques, S. Alberti, et al., "Malignant lesions in the ventral prostate of alloxan-induced diabetic rats," International Journal of Experimental Pathology, vol. 89, no. 4, pp. 276-283, 2008.
47. E. Suthagar, S. Soudamani, S. Yuvaraj, A. Ismail Khan, M. M. Aruldhas, and K. Balasubramanian, "Effects of streptozotocin (STZ)-induced diabetes and insulin replacement on rat ventral prostate," Biomedicine and Pharmacotherapy, vol. 63, no. 1, pp. 43-50, 2009.
48. M. Yono, M. Pouresmail, W. Takahashi, J. F. Flanagan, R. M. Weiss, and J. Latifpour, "Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes," Naunyn-Schmiedebergs Archives of Pharmacology, vol. 372, no. 3, pp. 251-255, 2005.
49. V. Chandrashekar, R. W. Steger, A. Bartke, C. T. Fadden, and S. G. Kienas, "Influence of diabetes on the gonadotropin response to the negative feedback effect of testosterone and hypothalamic neurotransmitter turnover in adult male rats," Neuroendocrinology, vol. 54, no. 1, pp. 30-35, 1991.
50. T. Abiko, A. Abiko, A. C. Clermont, et al., "Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation," Diabetes, vol. 52, no. 3, pp. 829-837, 2003.
51. N. E. Cameron, T. M. Gibson, M. R. Nangle, and M. A. Cotter, "Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes," Annals of the New York Academy of Sciences, vol. 1043, pp. 784-792, 2005.
52. G. S. A. Fernandes, C. D. B. Fernandez, K. E. Campos, D. C. Damasceno, J. A. Anselmo-Franci, and W. D. G. Kempinas, "Vitamin C partially attenuates male reproductive deficits in hyperglycemic rats," Reproductive Biology and Endocrinology, vol. 9, no. 1, article 100, 2011.
53. M. G. Gobbo, D. L. Ribeiro, S. R. Taboga, E. A. de Almeida, and R. M. Góes, "Oxidative stress markers and apoptosis in the prostate of diabetic rats and the influence of vitamin C treatment," Journal of Cellular Biochemistry, vol. 113, no. 7, pp. 2223-2233, 2012.
54. D. Koya, I.-K. Lee, H. Ishii, H. Kanoh, and G. L. King, "Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol," Journal of the American Society of Nephrology, vol. 8, no. 3, pp. 426-435, 1997.
55. R. Rahimi, S. Nikfar, B. Larijani, and M. Abdollahi, "Areview on the role of antioxidants in the management of diabetes and its complications," Biomedicine and Pharmacotherapy, vol. 59, no. 7, pp. 365-373, 2005.
56. F. G. Amaral, A. O. Turati, M. Barone, et al., "Melatoninsynthesis impairment as a new deleterious outcome of diabetes-derived hyperglycemia," Journal of Pineal Research, vol. 57, no. 1, pp. 67-79, 2014.
57. T. Wolden-Hanson, D. R. Mitton, R. L. McCants, et al., "Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat," Endocrinology, vol. 141, no. 2, pp. 487-497, 2000.
58. M. M. Bradford, "A rapid and sensitive method for the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye binding," Analytical Biochemistry, vol. 72, no. 1-2, pp. 248-254, 1976.
59. N. L. McGuire, K. Kangas, and G. E. Bentley, "Effects of melatonin on peripheral reproductive function: regulation of testicular GnIH and testosterone," Endocrinology, vol. 152, no. 9, pp. 3461-3470, 2011.
60. M. L. Dubocovich and M. Markowska, "Functional MT1 and MT2 melatonin receptors in mammals," Endocrine, vol. 27, no. 2, pp. 101-110, 2005.
61. E. J. Sudnikovich, Y. Z. Maksimchik, S. V. Zabrodskaya et al., "Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats," European Journal of Pharmacology, vol. 569, no. 3, pp. 180-187, 2007.
62. A. Agil, M. Navarro-Alarcõn, R. Ruiz, S. Abuhamadah, M.-Y. El-Mir, and G. F. Vázquez, "Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats," Journal of Pineal Research, vol. 50, no. 2, pp. 207-212, 2011.
63. S. Y. W. Shiu, W. Y. Leung, C. W. Tam, V. W. S. Liu, and K.-M. Yao, "Melatonin MT1 receptor-induced transcriptional up-regulation of p27Kip1 in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy," Journal of Pineal Research, vol. 54, no. 1, pp. 69-79, 2013.
64. M. G. Gobbo, C. F. P. Costa, D. G. H. Silva, E. A. Almeira, and R. M. Góes, "Biomarkers of oxidative stress in rat male reproductive organs under experimental diabetes and interference of melatonin treatment," Oxidative Medicine and Cellular Longevity. In press.
65. F. Radogna, L. Paternoster, M. C. Albertini, et al., "Melatonin as an apoptosis antagonist," Annals of the New York Academy of Sciences, vol. 1090, pp. 226-233, 2006.
66. S. Zhang, S. Zhao, L. Bai, M. Guan, J. Mo, and L. Lan, "Melatonin restores normal Bax and Bcl-2 protein expression in the subgranular zone of the dentate gyrus in pinealectomized rats," Neural Regeneration Research, vol. 6, no. 27, pp. 2129-2133, 2011.
67. S.-C. Wang, "PCNA: a silent housekeeper or a potential therapeutic target?" Trends in Pharmacological Sciences, vol. 35, no. 4, pp. 178-186, 2014.
68. A. Limanowski, B. Miskowiak, and B. Otulakowski, "Effects of melatonin, testosterone and the two hormones administered in parallel an ventral prostate of the rat treated with stilbestrol in the first day of life," Histology and Histopathology, vol. 10, no. 4, pp. 869-874, 1995.
69. W. Srivilai, B. Withyachumnarnkul, and W. Trakulrungsi, "Stereological changes in rat ventral prostate induced by melatonin," Journal of Pineal Research, vol. 6, no. 2, pp. 111-119, 1989.
70. Z. Lupowitz and N. Zisapel, "Hormonal interactions in human prostate tumor LNCaP cells,"TheJournal of Steroid Biochemistry and Molecular Biology, vol. 68, no. 1-2, pp. 83-88, 1999.
71. R. M. Sainz, J. C. Mayo, D.-X. Tan, J. León, L. Manchester, and R. J. Reiter, "Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism," Prostate, vol. 63, no. 1, pp. 29-43, 2005.
72. D. Hevia, J. C. Mayo, I. Quiros, C. Gomez-Cordoves, and R. M. Sainz, "Monitoring intracellular melatonin levels in human prostate normal and cancer cells by HPLC," Analytical and Bioanalytical Chemistry, vol. 397, no. 3, pp. 1235-1244, 2010.
73. D. L. Ribeiro, S. R. Taboga, and R. M. Góes, "Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate," International Journal of Experimental Pathology, vol. 90, no. 4, pp. 400-411, 2009.
74. D. Hevia, P. González-Menéndez, I. Quiros-González, et al., "Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer," Journal of Pineal Research, vol. 58, no. 2, pp. 234-250, 2015.
75. A. M. DeMarzo, W. G. Nelson, A. K. Meeker, and D. S. Coffey, "Stem cell features of benign and malignant prostate epithelial cells," Journal of Urology, vol. 160, no. 6, pp. 2381-2392, 1998.